Skip to Main Content

Paper Details

Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
Cardiovasc Drugs Ther
12
2021
ANGPTL3, APOC3, ASCVD, LDL-C, Lp[a], PCSK9, angiopoietin-like protein 3, apolipoprotein C3, atherosclerotic cardiovascular disease, cholesterol, human, lipoprotein (a), low density lipoprotein cholesterol, mAb, monoclonal antibody, proprotein convertase subtilisin/kexin type 9, siRNA, small interfering RNA
Author NameAffiliation
Xiaoming JiaBaylor College of Medicine
Christie M BallantyneBaylor College of Medicine
Christie M BallantyneBaylor College of Medicine
Salim S ViraniBaylor College of Medicine
Salim S ViraniMichael E. DeBakey Veterans Affairs Medical Center
Salim S ViraniHealth Services Research and Development Center for Innovations, Michael E. DeBakey Veterans Affairs Medical Center
  • 1 - 6

Datasets

Release 1.2